SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?


To: Paul S. who wrote (497)4/29/1998 11:36:00 AM
From: Paul S.  Read Replies (1) | Respond to of 1185
 
Just saw this in the Financial Post.

MARKET ACTION

Nortran Pharmaceuticals Inc. (NRT/VSE), up $0.44 to $2.70, on volume of 935,150 shares.

Shares of the Vancouver-based drug-development company rose 19% yesterday in triple the average daily volume to close at a 52-week high.

The company develops drugs to prevent irregular heartbeats - a condition which in some cases can lead to sudden death - and is rumored to be negotiating a licensing deal with a major pharmaceutical maker soon, said Brook Riggins, an analyst with Canaccord Capital Corp.

Also, the stock has been rising on Monday's announced brokered private placement of five million special warrants, Riggins said.



To: Paul S. who wrote (497)4/29/1998 2:48:00 PM
From: Saracen  Read Replies (1) | Respond to of 1185
 
From my limited knowledge of the requirements for a NASDAQ small cap listing, I would guess that Nortran does meet all of these except for the share price (need US$4 for initial listing?). However, I believe that management's priority at this time is the T.S.E. listing, which is a great stepping stone towards ultimately listing in the U.S.

Here is the latest rumor that I just heard this morning:

There is a Nortran directors' meeting in the next few days to approve the deal with whomever is the major drug company. Remember - this is simply a rumor, and so should be taken with a grain of salt.